Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has issued an update.
IRLAB Therapeutics announced the departure of their CFO, Viktor Siewertz, who has been instrumental in the company’s growth and development over the past decade. His exit marks a significant change in the company’s leadership as they begin the search for a new CFO, potentially impacting their strategic direction and stakeholder confidence.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing transformative treatments for all stages of Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research group, the company has a diverse portfolio that includes Mesdopetam, Pirepemat, and IRL757, among others, and is listed on Nasdaq Stockholm.
YTD Price Performance: -68.72%
Average Trading Volume: 93,469
Technical Sentiment Signal: Sell
Current Market Cap: SEK269.9M
For an in-depth examination of IRLAB.A stock, go to TipRanks’ Overview page.